PDF(Pubmed)
Abstract：
UNASSIGNED: The effects of pre-anesthetic single-dose oral pimobendan during inhalational anesthesia, including the comparison with the effects of single intravenous pimobendan under anesthesia, remain unexplored. Therefore, this study aimed to determine changes in hemodynamic and echocardiographic parameters induced by pre-anesthetic administration of oral pimobendan under isoflurane general anesthesia and to compare them with those induced by intravenous pimobendan.
UNASSIGNED: Thirteen clinically normal dogs (4 laboratory and 9 client-owned dogs) with no clinical signs and not on any medical treatment were included. Anesthesia was performed three times: no pimobendan (Control), oral pimobendan (PIMO PO, 0.3 mg/kg), and intravenous pimobendan (PIMO IV, 0.15 mg/kg). Echocardiographic and hemodynamic parameters were monitored at 30-min intervals in all groups.
UNASSIGNED: Compared to the Control group, end-systolic volume index (ESVI) and normalized left ventricular internal diameter at end-systole (LVIDSN) were significantly lower, and fractional shortening (FS) and ejection fraction (EF) were significantly higher in the PIMO PO and IV groups (p < 0.001). Global radial strain (GRS) was significantly higher in the PIMO PO and IV groups (p = 0.015).
UNASSIGNED: Under general anesthesia, oral pimobendan preserved LV systolic and myocardial function in a manner comparable to intravenous pimobendan. Pre-anesthetic administration of oral pimobendan can be used to compensate for cardiac systolic function in dogs who require therapeutic and diagnostic procedures under general anesthesia with potential risk of circulatory failure.
UNASSIGNED: Thirteen clinically normal dogs (4 laboratory and 9 client-owned dogs) with no clinical signs and not on any medical treatment were included. Anesthesia was performed three times: no pimobendan (Control), oral pimobendan (PIMO PO, 0.3 mg/kg), and intravenous pimobendan (PIMO IV, 0.15 mg/kg). Echocardiographic and hemodynamic parameters were monitored at 30-min intervals in all groups.
UNASSIGNED: Compared to the Control group, end-systolic volume index (ESVI) and normalized left ventricular internal diameter at end-systole (LVIDSN) were significantly lower, and fractional shortening (FS) and ejection fraction (EF) were significantly higher in the PIMO PO and IV groups (p < 0.001). Global radial strain (GRS) was significantly higher in the PIMO PO and IV groups (p = 0.015).
UNASSIGNED: Under general anesthesia, oral pimobendan preserved LV systolic and myocardial function in a manner comparable to intravenous pimobendan. Pre-anesthetic administration of oral pimobendan can be used to compensate for cardiac systolic function in dogs who require therapeutic and diagnostic procedures under general anesthesia with potential risk of circulatory failure.
摘要：
■吸入麻醉期间麻醉前单剂量口服匹莫苯的效果，包括与麻醉下单次静脉注射匹莫苯的效果的比较，仍未探索。因此,本研究旨在确定异氟烷全身麻醉下预麻醉给药口服匹莫丹引起的血流动力学和超声心动图参数变化,并与静脉注射匹莫丹引起的变化进行比较.
■包括13只临床正常的狗（4只实验室和9只客户拥有的狗），没有临床症状，也没有进行任何药物治疗。麻醉进行了三次：没有匹莫苯丹（对照），口服匹莫苯丹(PIMOPO，0.3mg/kg)，和静脉注射匹莫苯丹(PIMOIV，0.15mg/kg)。在所有组中每隔30分钟监测超声心动图和血液动力学参数。
■与对照组相比，收缩末期容积指数(ESVI)和收缩末期标准化左心室内径(LVIDSN)显著降低,PIMOPO和IV组的缩短分数（FS）和射血分数（EF）显着升高（p<0.001）。PIMOPO和IV组的全局径向应变（GRS）明显更高（p=0.015）。
■全身麻醉，口服匹莫苯以与静脉注射匹莫苯相当的方式保持LV收缩和心肌功能。口服匹莫苯的麻醉前给药可用于补偿在全身麻醉下需要治疗和诊断程序的狗的心脏收缩功能，并有潜在的循环衰竭风险。
■包括13只临床正常的狗（4只实验室和9只客户拥有的狗），没有临床症状，也没有进行任何药物治疗。麻醉进行了三次：没有匹莫苯丹（对照），口服匹莫苯丹(PIMOPO，0.3mg/kg)，和静脉注射匹莫苯丹(PIMOIV，0.15mg/kg)。在所有组中每隔30分钟监测超声心动图和血液动力学参数。
■与对照组相比，收缩末期容积指数(ESVI)和收缩末期标准化左心室内径(LVIDSN)显著降低,PIMOPO和IV组的缩短分数（FS）和射血分数（EF）显着升高（p<0.001）。PIMOPO和IV组的全局径向应变（GRS）明显更高（p=0.015）。
■全身麻醉，口服匹莫苯以与静脉注射匹莫苯相当的方式保持LV收缩和心肌功能。口服匹莫苯的麻醉前给药可用于补偿在全身麻醉下需要治疗和诊断程序的狗的心脏收缩功能，并有潜在的循环衰竭风险。
